

# 11<sup>th</sup> International Transplant and Cellular Therapy Course

Barcelona, Spain | 11-13 September 2026



## WORD OF WELCOME

Dear Friends and Colleagues,

Welcome to the 11th International Transplant and Cellular Therapy Course.

One of the greatest privileges of working in transplantation and cellular therapy is the opportunity to grow alongside a field that never stands still. Every year brings new scientific discoveries, innovative therapeutic approaches, and fresh opportunities to improve the lives of our patients. Equally rewarding is the chance to share this journey with an international community united by a common passion for excellence, collaboration, and innovation.

We are delighted to welcome you to Barcelona for three days of scientific exchange, interactive learning, and professional networking. This year's programme has been carefully designed to provide a comprehensive overview of the latest developments in transplantation and cellular therapies, combining state-of-the-art lectures with case-based discussions, parallel adult and paediatric sessions, and opportunities to engage directly with leading experts.

Highlights of the course include sessions on cell therapy, transplant immunology, graft-versus-host disease, infectious complications, the microbiome, long-term outcomes, and the expanding role of cellular therapies in autoimmune diseases. We are also honoured to host a keynote lecture on Redefining Hodgkin Lymphoma Through Precision Medicine.

Supporting the next generation of professionals remains a cornerstone of this course. Through oral presentations, poster flash talks, and EBMT educational grants, we aim to foster collaboration, encourage scientific discussion, and provide a platform for emerging investigators from across Europe and beyond.

Whether you are joining us as a long-standing member of the transplant community or attending for the first time, we hope this course will inspire new ideas, strengthen existing collaborations, and create lasting professional connections.

Thank you for being part of this experience. We wish you a stimulating, enjoyable, and memorable course, and we look forward to welcoming you to Barcelona on 11-13 September 2026.

## The Organising Committee

**Esra Gülderen**, *EBMT Trainee Committee Co-Chair*

**Mette Hazenberg**, *EBMT Treasurer*

**Claire Horgan**, *EBMT Educational Task Force Representative for Paediatric Diseases Working Party*

**Krzysztof Katwak**, *Scientific Council co-Chair with Research & Sciences Portfolio and Paediatric Diseases Working Party Chair*

**Hilda Mekelenkamp**, *President, Nurses Group*

**Ali Bazarbachi**, *Scientific Council Representative with the Education Portfolio and Lymphoma Working Party Chair*

**Mohamad Mohty**, *EBMT Past President (2014-2018)*

**Alex Rampotas**, *EBMT Trainee Committee Co-Chair*

**Annalisa Ruggeri**, *Past Scientific Council Representative with Education Portfolio and Cellular Therapy & Immunobiology Working Party Chair*

**Donal McLornan**, *Past Scientific Council co-Chair with Research & Sciences Portfolio*

**Anna Sureda**, *EBMT Past President (2022-2026)*

**Ibrahim Yakoub-Agha**, *EBMT President*

## Hear from Experts Shaping Transplant and Cellular Therapy for Patients with Haemoglobinopathies

Discover expert-led webinars, podcasts and presentations to support your clinical practice.




### PODCAST

#### Handling difficult conversations with patients about transplant

Dr Jenna Love, Natasha Lewis and Dr Nibras Naami share key considerations for discussing transplant with patients.

Listen >



### WEBINAR

#### Patient care during transplant and beyond

Gain insights into supporting patients and families throughout the haemoglobinopathy transplant journey.

Watch >



### HIGHLIGHTS

#### Highlights from the EBMT 2026 Congress

Experts Fabio Giglio and Michelle Kenyon reflect on key highlights from the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT).

View >

Scan the QR code to explore more expert-led education on the GlobeIN website or visit [globeinportal.com](https://globeinportal.com)



The content enclosed is intended only for healthcare professionals interested in haemoglobinopathies.

GlobeIN is an educational programme organised and funded entirely by Vertex Pharmaceuticals (Europe) Limited. All content is developed by the scientific committee and speakers for each meeting, with support from a medical education agency acting as Secretariat. Vertex Pharmaceuticals (Europe) Limited has had an opportunity to review the materials for scientific accuracy and fair balance. AC-02-2600131 | September 2026

©2026 Vertex Pharmaceuticals Incorporated.

# 11<sup>th</sup> International Transplant and Cellular Therapy Course

Barcelona, Spain | 11-13 September 2026



**Friday, 11 September 2026**

Plenary Room: *Paranimf*

09:00 – 10:30

## **Session I: Welcome & Kick-off**

**Chairs:** *Esra Gülderen (FI) & Alex Rampotas (UK)*

09:00 – 09:10

Welcome from the Scientific Council Chair and EBMT Research Meeting introduction

Antonio Risitano (IT)

09:10 – 09:30

Principles of hematopoietic cell transplantation

Sebastian Giebel (PL)

09:30 – 09:50

Immune reconstitution

Esra Gülderen (FI)

09:50 – 10:10

Current landscape of CAR-T & T cell engineering

Alex Rampotas (UK)

10:10 – 10:20

*Case Presentation:* When the foundations are rocked - donor withdrawal post start of conditioning

Lorna Neill (UK)

10:20 – 10:30

Discussion

10:30 – 11:00

## **Coffee Break**

11:00 – 12:30

## **Session II: Foundations of Transplantation and Cellular Therapy**

**Chairs:** *Alex Rampotas (UK) & Giorgio Orofino (IT)*

11:00 – 11:20

The HLA system and donor selection

Neema Mayor (UK)

11:20 – 11:40

Mobilization, collection, and cryopreservation of HSC

Patrick Hayden (IE)

11:40 – 12:00

Conditioning regimens

Fabio Ciceri (IT)

12:00 – 12:10

*Case Presentation:* Peri-allograft use of momelotinib in myelofibrosis: outcomes And Impact of discontinuation timing on engraftment kinetics

Trung Ngo (UK)

12:10 – 12:30

Discussion

12:30 – 13:15

## **Lunch Break**

13:15 - 14:00

## **Industry Symposium kindly sponsored by Therakos:**

### **"Advancing immunomodulation in GvHD special populations"**

Leader Chair: **Prof Hildegard Greinix**, Medical University of Vienna, Austria

13:15 – 13:35

NIH 2025 Chronic GvHD consensus: Unmet needs and considerations for immunomodulatory approaches

**Prof Hildegard Greinix**, Medical University of Vienna, Austria

13:35 – 13:55

Pediatric GvHD management: Clinical considerations for ECP use

**Prof Andrew Gennery**, Great North Children's Hospital Newcastle, United Kingdom

13:55 – 14:00

Q&A

14:00 – 15:30

## **Session III: Harnessing Immunity**

**Chairs:** *Raffaella Greco (IT) & Marcin Jacinski (PL)*

14:00 – 14:20

Cellular therapies in Autoimmune disease

Raffaella Greco (IT)

14:20 – 14:40

Biology of disease relapse

Luca Vago (IT)

14:40 – 15:00

Immune therapies for post-transplant relapse

Simona Pagliuca (FR)

15:00 – 15:10

*Case Presentation:* Consolidation of dual MAPK inhibitor therapy by allograft in histiocytic sarcoma: an example of allograft after remission induction using target therapies in a rare haematological neoplasm

Kate Milne (UK)

15:10 – 15:30

Discussion

15:30 – 16:00

## **Coffee Break**

# 11<sup>th</sup> International Transplant and Cellular Therapy Course

Barcelona, Spain | 11-13 September 2026



**Friday, 11 September 2026**

Plenary Room: *Paranimf*

|                      |                                                                                                                                                                                                                         |                             |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|
| <b>16:00 – 17:30</b> | <b>Session IV: Post-Transplant Complication Challenges</b>                                                                                                                                                              |                             |
|                      | <b>Chairs:</b> <i>Annalisa Ruggeri (IT) &amp; Valentín Ortiz-Maldonado (ES)</i>                                                                                                                                         |                             |
| <b>16:00 – 16:20</b> | Graft Failure                                                                                                                                                                                                           | Annalisa Ruggeri (IT)       |
| <b>16:20 – 16:40</b> | TMA & VOD                                                                                                                                                                                                               | Giorgio Orofino (IT)        |
| <b>16:40 – 17:00</b> | Measurable Residual Disease post allo-HCT                                                                                                                                                                               | Jürgen Kuball (NL)          |
| <b>17:00 – 17:10</b> | <i>Case Presentation:</i> Secondary HLH following autologous HSCT: a case highlighting Diagnostic complexity and management                                                                                             |                             |
| <b>17:10 – 17:30</b> | Discussion                                                                                                                                                                                                              | Meiramgu Yussupova (KZ)     |
| <b>17:30 – 18:40</b> | <b>Flash-Talk Session</b>                                                                                                                                                                                               |                             |
|                      | <b>Chairs:</b> <i>Donal McLornan (UK) &amp; Annalisa Ruggeri (IT)</i>                                                                                                                                                   |                             |
| <b>17:30 – 17:35</b> | Efficacy of Teduglutide in Refractory aGvHD after Haploidentical Allogeneic HCT                                                                                                                                         | Matteo Cristante (IT)       |
| <b>17:35 – 17:40</b> | Ongoing Remission After Allogeneic Stem Cell Transplantation with Reduced-Intensity Conditioning in Refractory DLBCL After Failure of Multiple Prior Therapy Lines Including CAR T-Cells                                |                             |
| <b>17:40 – 17:45</b> | Transient lineage switch in ALL – to allograft or not?                                                                                                                                                                  | Rita Varga (DE)             |
| <b>17:45 – 17:50</b> | Clinical challenges in the treatment of DLBCL with car-t cells                                                                                                                                                          | Adrian Matthew Maraj (UK)   |
| <b>17:50 – 17:55</b> | Two Mutations, One Storm: Metabolic-Immune Crosstalk in EBV-Triggered Hemophagocytic Lymphohistiocytosis                                                                                                                | Maria B. Villacres (ES)     |
| <b>17:55 – 18:00</b> | Reversible cerebral vasoconstriction syndrome during allogeneic hematopoietic stem cell transplantation in a patient with sickle cell disease: a case report                                                            | Sefika Akyol (TR)           |
| <b>18:00 – 18:05</b> | Early Secondary Graft Failure After Complete Donor Chimerism with Subsequent Autologous Hematopoietic Reconstitution Following Haploidentical Sibling Allogeneic HSCT for Relapsed B-Cell Acute Lymphoblastic Leukaemia | Rafael Uliano (BR)          |
| <b>18:05 – 18:10</b> | When Mobilization Fails: Bone Marrow Harvest as a Salvage Strategy for ASCT in Heavily Pretreated PCNSL                                                                                                                 | Rene Jr. Amadore (PH)       |
| <b>18:10 – 18:15</b> | Severe Hypercholesterolemia Due to Lipoprotein X as the Presenting Manifestation of Hepatic Chronic Graft-Versus-Host Disease after Haploidentical Stem Cell Transplantation                                            | Vincenzo D'Agostino (IT)    |
| <b>18:15 – 18:20</b> | A tale of recurrent thromboses and complex endothelial syndromes in allogeneic stem cell transplantation for acute myeloid leukaemia                                                                                    | Caroline del Castanhel (CL) |
| <b>18:20 – 18:25</b> | Early Haploidentical Hematopoietic Stem Cell Transplantation for SMARCD2-Related Neutrophil-Specific Granule Deficiency in Infancy: A Case Report                                                                       | Katrin Alizadeh (UK)        |
| <b>18:25 – 18:30</b> | Interaction Between In Vivo T-Cell Depletion and Pharmacokinetic-Guided Busulfan Conditioning in Acute Myeloid Leukaemia in Complete Remission                                                                          | Deniz Honamli (TR)          |
| <b>18:30 – 18:35</b> | Transplanted with a Broken Heart                                                                                                                                                                                        | Corinne Spoto (IT)          |
| <b>18:35 – 18:40</b> | Complex Management of Relapsed/Refractory FLT3-Positive Acute Myeloid Leukaemia with Simultaneous Thrombotic and Haemorrhagic Complications Following Stem Cell Transplantation                                         | Jaime D. Pallo (ES)         |
|                      |                                                                                                                                                                                                                         | Ahd Hassan (AE)             |

# 11<sup>th</sup> International Transplant and Cellular Therapy Course

Barcelona, Spain | 11-13 September 2026



**Saturday, 12 September 2026**

Main Track | *Paranimf*

09:00 – 10:30

## **Session V: Indications for allogeneic HCT in Adults (part I)**

**Chairs** *Emmanuel Häfliger (CH) & Fabio Ciceri (IT)*

09:00 – 09:15

Introductory Case-based: Indications of HCT in MPN

09:15 – 09:35

Indications of HCT in MPN

09:35 – 09:50

Introductory Case-based: Indications of HCT in MDS

09:50 – 10:10

Indications of HCT in MDS

10:10 – 10:30

Discussion

Trung Ngo (UK)

Donal McLornan (UK)

Marcin Jacinski (PL)

Joanna Drozd-Sokolowska (PL)

10:30 – 11:00

## **Coffee Break**

11:00 – 12:30

## **Session V: Indications for allogeneic HCT in Adults (part II)**

**Chairs:** *Joanna Drozd-Sokolowska (PL) & Trung Ngo (UK)*

11:00 – 11:15

Introductory Case-based: Indications of HCT in AML

11:15 – 11:35

Indications of HCT in AML

11:35 – 11:50

Introductory Case-based: Indications of HCT In Bone marrow failures

11:50 – 12:10

Indications of HCT in Bone marrow failures

12:10 – 12:30

Discussion

Greta Morello (IT)

Fabio Ciceri (IT)

Emmanuel Häfliger (CH)

Alicia Rovó (CH)

12:30 – 13:15

## **Lunch Break**

13:15 – 14:05

## **Oral Session**

**Chairs:** *Raffaella Greco (IT) & Esra Gülderer (FI)*

13:15 – 13:22

*Case Presentation:* Successful management of refractory primary central nervous system lymphoma with tandem autologous stem cell transplantation and CAR-T: early-sustained response and severe ICANS

Jorge Illarramendi (FR)

13:22 – 13:29

*Case Presentation:* Transfusion-free allogeneic haploidentical hematopoietic Cell transplant

Strategy for Sezary syndrome: harmonizing patient preferences with high-risk transplants Hector A. Vaquera (MX)

13:29 – 13:36

*Case Presentation:* Donor-derived CD19 CAR-T cells as a second transplant-sparing option in extramedullary relapse of acute lymphoblastic leukaemia after haploidentical stem cell transplantation

Athanasios Gakopoulos (GR)

13:36 – 13:43

*Case Presentation:* Successful immune reconstitution-guided approach in Severe ruxolitinib-refractory gastrointestinal acute GvHD

Gaia Tomadini (IT)

13:43 – 13:50

*Case Presentation:* Post-transplant allogeneic boost as MRD-guided strategy in CALR-mutated myelofibrosis

Marta Ricci (IT)

13:50 – 13:57

*Case Presentation:* Rituximab-refractory EBV-PTLD after ATG-based Allogeneic HSCT for aplastic anaemia successfully treated with donor-derived EBV-specific T cells

Lena Stabel (DE)

13:57 – 14:04

*Case Presentation:* Severe EBV-driven hemophagocytic lymphohistiocytosis associated with VAV1 variants treated with allogeneic hematopoietic cell transplantation

Lucrecia Oses (AR)

14:05 – 15:30

## **Session VI: Advances in Multiple Myeloma**

**Chairs:** *Lydia Lee (UK) & Ilse Kuipers (NL)*

14:05 – 14:25

Transplantation in Multiple Myeloma and Monoclonal Gammopathies

Patrick Hayden (IE)

14:25 – 14:45

CAR-T in Multiple Myeloma

Lydia Lee (UK)

14:45 – 15:05

Management of CRS & ICANS

Valentín Ortiz-Maldonado (ES)

15:05 – 15:15

*Case Presentation:* CRS and HLH following anti-BCMA CAR-T for Multiple Myeloma

David G. Hernandez (IT)

15:15 – 15:30

Discussion

15:30 – 16:00

## **Coffee Break**

# 11<sup>th</sup> International Transplant and Cellular Therapy Course

Barcelona, Spain | 11-13 September 2026



**Saturday, 12 September 2026**

Main Track | *Paranimf*

**16:00 – 17:30**

**Session VII: Everything Lymphoid**

**Chairs:** Ali Bazarbachi (LB) & Greta Morello (IT)

**16:00 – 16:20**

Transplant for ALL

**16:20 – 16:40**

Transplant for Hodgkin Lymphoma

**16:40 – 17:00**

Cellular Therapy and HCT in Non Hodgkin Lymphoma

**17:00 – 17:10**

*Case Presentation:* Role of radiotherapy as holding to CAR-T cell therapy and early consolidation: A case of CNS-relapsed PMBCL

**17:10 – 17:30**

Discussion

Sebastian Giebel (PL)

Ali Bazarbachi (LB)

Ilse Kuipers (NL)

Vincenzo Cuzzupi (IT)

# 11<sup>th</sup> International Transplant and Cellular Therapy Course

Barcelona, Spain | 11-13 September 2026



**Saturday, 12 September 2026**  
Paediatrics' Track | Aula Magna

|               |                                                                                                                                                                                |                                |
|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|
| 09:00 – 10:30 | <b>Session I: Hot topics in paediatric leukaemia</b><br><b>Chairs:</b> Krzysztof Kałwak (PL) & Claire Horgan (UK)                                                              |                                |
| 09:00 – 09:20 | Second transplant or CAR-T cell therapy in case of ALL relapse posttransplant?                                                                                                 | Krzysztof Kałwak (PL)          |
| 09:20 – 09:40 | T-replete cord as a transplant platform in high risk AML                                                                                                                       | Claire Horgan (UK)             |
| 09:40 – 10:00 | CART Therapy in T-ALL                                                                                                                                                          | Robert Chiesa (UK)             |
| 10:00 – 10:10 | <i>Case Presentation:</i> Sequential Tisagenlecleucel and Haploidentical HSCT in Relapsed Paediatric B-ALL After Prior Allogeneic Transplant                                   | Alexandra-Flavia Tule (RO)     |
| 10:10 – 10:15 | Launch of the EBMT Paediatric Masterclass                                                                                                                                      | Claire Horgan (UK)             |
| 10:15 – 10:30 | Discussion                                                                                                                                                                     |                                |
| 10:30 – 11:00 | <b>Coffee Break</b>                                                                                                                                                            |                                |
| 11:00 – 12:30 | <b>Session II: Inborn Errors Working Party (IEWP)</b><br><b>Chairs:</b> Robert Chiesa (UK) & Lisa Ott de Bruin (NL)                                                            |                                |
| 11:00 – 11:20 | Transplant for osteopetrosis- lessons learnt from the last 3 decades                                                                                                           | Robert Chiesa (UK)             |
| 11:20 – 11:40 | HCT in Chediak Higashi                                                                                                                                                         | Reem Elfeky (UK)               |
| 11:40 – 12:00 | Immunology in Haematology and Haematology in Immunology: a joint venture or a separate field?                                                                                  | Benedetta di Majo (IT)         |
| 12:00 – 12:10 | <i>Case Presentation:</i> Lymphoproliferative Disease in CTPS1 Deficiency: Single Centre                                                                                       |                                |
| 12:10 – 12:30 | Experience of Hematopoietic Stem Cell Transplantation and Adoptive Cellular Therapies                                                                                          | Michail Matalliotakis (UK)     |
| 12:10 – 12:30 | Discussion                                                                                                                                                                     |                                |
| 12:30 – 13:15 | <b>Lunch Break</b>                                                                                                                                                             |                                |
| 13:15 – 14:05 | <b>Oral Session</b><br><b>Chairs:</b> Hilda Mekelenkamp (NL) & Benedetta di Majo (IT)                                                                                          |                                |
| 13:15 – 13:22 | <i>Case Presentation:</i> Donor-Derived Virus-Specific T Cells in the Treatment of Refractory Adenovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation | Agnieszka Sobkowiak (PL)       |
| 13:22 – 13:29 | Relapsed/Refractory ALK-Positive Anaplastic Large Cell Lymphoma in a Child: Sequential Salvage, Allogeneic HSCT, and Durable Remission with Crizotinib Post-Transplant Relapse | Ankita Chakraborty (IN)        |
| 13:29 – 13:36 | Hematopoietic stem cell transplant to rescue hypomorphic RAG deficiency accompanied by immune dysregulation                                                                    | Amanda Campbell (US)           |
| 13:36 – 13:43 | Ruxolitinib-mediated Bridging to HSCT and Therapy of Intestinal GvHD in Neonatal Artemis-SCID                                                                                  | Judit Nyiro (DE)               |
| 13:43 – 13:50 | Three cases of X-Linked Adrenoleukodystrophy (X-ALD) with distinct family histories managed with allogeneic stem cell transplantation                                          | Kalasekhar Vijaya (UK)         |
| 13:50 – 13:57 | Invasive Pulmonary Mucormycosis During Treatment of Post-Transplant Relapse of Acute Myeloid Leukemia: A Therapeutic Challenge                                                 | Zorana Janković Jovanović (RS) |
| 13:57 – 14:04 | Bridging Severe Infection to Cure: Haplo-identical HSCT in IL2RG-Deficient SCID with ARDS and Complex Post-Transplant Immune Recovery                                          | Shivani Patel (IN)             |
| 14:05 – 15:30 | <b>Session III: Haemoglobinopathies WP + Severe Aplastic Anaemia WP + MDS-EWOG</b><br><b>Chairs:</b> Carlo Dufour (IT) & Selim Corbacioglu (DE)                                |                                |
| 14:05 – 14:25 | HCT for Telemeropathies                                                                                                                                                        | Carlo Dufour (IT)              |
| 14:25 – 14:45 | HCT for Paediatric MDS                                                                                                                                                         | Luca Vinci (DE)                |
| 14:45 – 15:05 | HCT and gene therapy for Paediatric Haemoglobinopathies in 2026                                                                                                                | Selim Corbacioglu (DE)         |
| 15:05 – 15:15 | <i>Case Presentation:</i> Hematopoietic Cell Transplantation in Paediatric Unstable Hemoglobinopathies: Two Rare Cases with Sustained Donor Chimerism and Long-Term Follow-Up  | Annie Costa (BR)               |
| 15:15 – 15:30 | Discussion                                                                                                                                                                     |                                |

# 11<sup>th</sup> International Transplant and Cellular Therapy Course

Barcelona, Spain | 11-13 September 2026



**Sunday, 13 September 2026**

Main Track | Paranimf

**09:00 – 10:30**

## **Session VIII: GvHD, Microbiome and Long-Term Outcomes**

**Chairs:** *Mette Hazenberg (NL) & Michelle Kenyon (UK)*

**09:00 – 09:20**

Acute GvHD prophylaxis and therapy

**09:20 – 09:40**

Chronic GvHD biology and management

**09:40 – 10:00**

Microbiome and cellular therapy

**10:00 – 10:20**

Late effects surveillance post allo-HCT

**10:20 – 10:30**

*Case Presentation:* Persistent tissue-invasive CMV disease mimicking steroid-refractory GVHD after allogeneic hematopoietic stem cell transplantation

Zinaida Perić (HR)

Mette Hazenberg (NL)

Florent Malard (FR)

Michelle Kenyon (UK)

Francisco Marrero (SP)

**10:30 – 11:00**

## **Coffee Break**

**11:00 – 12:30**

## **Session IX: Modulating Immunity, Managing Infections**

**Chairs:** *Giorgio Orofino (IT) & Rafaella Greco (IT)*

**11:00 – 11:20**

Management of Infections Post-HCT

**11:20 – 11:40**

Management of Infections Post-CAR-T

**11:40 – 12:00**

Multidisciplinary Perspectives on Infection Control

**12:00 – 12:10**

*Case Presentation:* Decoupling antiviral efficacy from toxicity: Maribavir enables CMV-specific immune reconstitution after allo-HSCT

**12:10 – 12:30**

Discussion

Elif Ince (TR)

Lidia Gil (PL)

Hilda Mekelenkamp (NL)

Clelia Monteleone (IT)

**12:30 – 13:00**

## **Closing Remarks and Poster Awards**

**Chairs:** *Ibrahim Yakoub-Agha (FR) & Esra Gülderen (FI)*

**12:30 – 12:45**

What is the EBMT and its mission in cell therapy?

**12:45 – 13:00**

Poster Awards

Ibrahim Yakoub-Agha (FR)

Ibrahim Yakoub-Agha (FR)

Krzysztof Kałwak (PL)

# 11<sup>th</sup> International Transplant and Cellular Therapy Course

Barcelona, Spain | 11-13 September 2026



**Friday, 11 September 2026 – Sunday, 13 September 2026**

Poster Exhibition | Foyer

Take advantage of the networking opportunities during the coffee breaks and lunch to explore the poster exhibition, meet the presenters, and engage in scientific discussion.

**POSTER 01 | Ganesan Subramanian (IN):**

*DADA =2 - Diagnosis and Management by HSCT*

**POSTER 02 | Nithya Seshadri (IN):**

*Sequential Haploidentical Stem Cell Transplantation in Refractory Pediatric KMT2A-Rearranged Acute Myeloid Leukemia: Navigating Relapse, Hyperinflammation, and Immune Reconstitution*

**POSTER 03 | Julia de Paula (BR):**

*Walking the Tightrope: The Treacherous Path in the Management of an Atypical and Severe Graft-versus-Host Disease Case*

**POSTER 04 | Bibigaisha Adusheva (KZ):**

*The Use of Pembrolizumab as Monotherapy and in Combination with Chemotherapy in the Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma*

**POSTER 05 | Fatema Al Wusibai (SA):**

*Artificial Intelligence and Machine Learning for Prediction of Early Complications Following Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-analysis*

**POSTER 06 | Julieth Obedi Elias (TZ):**

*Patterns of Bacterial, Viral, Parasitic and Fungal Infections in Pediatric Patients Post Hematopoietic Stem Cell Transplant: A Tanzanian Single-Center Experience Over the Past 3 Years*

**POSTER 07 | Gaia Tomadini (IT):**

*Successful Immune Reconstitution-Guided Approach in Severe Ruxolitinib Refractory Gastrointestinal Acute GvHD*

**POSTER 08 | Marwa Ahmed (AE):**

*Acute Panmyelosis with Myelofibrosis (APMF)*

**POSTER 09 | Sayna Samaee (GB):**

*Unexplained Confusion Following Matched Unrelated Donor Allogeneic Stem Cell Transplantation for Accelerated Phase JAK2-Mutated Myeloproliferative Neoplasm*

**POSTER 10 | Luciana de la Rúa (AR):**

*Richter Syndrome: The Challenge of Achieving Pre-Transplant Remission*

**POSTER 11 | Nazar Klimov (RU):**

*Belumosudil in Children with Refractory Chronic Graft-versus-Host Disease: A Single-Center Experience*

# 11<sup>th</sup> International Transplant and Cellular Therapy Course

Barcelona, Spain | 11-13 September 2026



## WITH THANKS TO OUR SPONSORS

Industry Symposium Partner



Silver Partners



Meeting Supporter

